Evidence map›Paper›PMID 28811622›Full record

ArticleScientific reports2017

Dipeptidyl peptidase-4 inhibitors and cancer risk in patients with type 2 diabetes: a meta-analysis of randomized clinical trials.

Ming Zhao, Jiayi Chen, Yanyan Yuan, Zuquan Zou, Xiaolong Lai, Daud M Rahmani, Fuyan Wang, Yang Xi, Qin Huang, Shizhong Bu

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 44 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 1 pooled it
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Observational
  6. Review
  7. Article
  8. Article
  9. Article
  10. Observational
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Ming ZhaoRunliang Diabetes Laboratory, Diabetes Research Center, School of Medicine, Ningbo University, 315211, Ningbo, China.
Jiayi ChenRunliang Diabetes Laboratory, Diabetes Research Center, School of Medicine, Ningbo University, 315211, Ningbo, China.
Yanyan YuanRunliang Diabetes Laboratory, Diabetes Research Center, School of Medicine, Ningbo University, 315211, Ningbo, China.
Zuquan ZouRunliang Diabetes Laboratory, Diabetes Research Center, School of Medicine, Ningbo University, 315211, Ningbo, China.
Xiaolong LaiRunliang Diabetes Laboratory, Diabetes Research Center, School of Medicine, Ningbo University, 315211, Ningbo, China.
Daud M RahmaniRunliang Diabetes Laboratory, Diabetes Research Center, School of Medicine, Ningbo University, 315211, Ningbo, China.
Fuyan WangRunliang Diabetes Laboratory, Diabetes Research Center, School of Medicine, Ningbo University, 315211, Ningbo, China.
Yang XiRunliang Diabetes Laboratory, Diabetes Research Center, School of Medicine, Ningbo University, 315211, Ningbo, China.
Qin HuangDepartment of Endocrinology, Changhai Hospital, Second Military Medical University, 200433, Shanghai, China. qxinyi1220@163.com.
Shizhong BuRunliang Diabetes Laboratory, Diabetes Research Center, School of Medicine, Ningbo University, 315211, Ningbo, China. bushizhongbu@nbu.edu.cn.ORCID 0000-0001-5196-6030
Ningbo University · CNSecond Military Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Some recent studies have suggested that the use of dipeptidyl peptidase-4 inhibitors (DPP4i) is associated with cancer development. However, some other studies suggest no such association. The aim of the present study was to evaluate the effect of DPP4i on the risk of developing cancers. The electronic databases PubMed, Medline, EMBASE, Web of Science and Cochrane Library and the clinical trial registry were searched for published and unpublished randomized clinical trials on humans. Eligible studies were RCTs conducted in patients with type 2 diabetes mellitus, comparing DPP4i with a placebo or other active drugs. A total of 72 trials with 35,768 and 33,319 patients enrolled for DPP4i and the comparison drugs, respectively. Overall, no significant associations were detected between the use of DPP4i and cancer development, in comparison with the use of other active drugs or placebo. The results were consistent across pre-defined subgroups stratified by type of DPP4i, type of cancer, drug for comparison, trial duration, or baseline characteristics. The results of this meta-analysis suggest that patients with type 2 diabetes treated with DPP4i do not have a higher risk of developing cancers than patients treated with a placebo or other drugs.

Identifiers

PMID28811622
PMCPMC5557948
OpenAlexW2742281288

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.